<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">53447</article-id><article-id pub-id-type="doi">10.7554/eLife.53447</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Suppressing proteasome mediated processing of Topoisomerase II DNA-protein complexes preserves genome integrity</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-164117"><name><surname>Sciascia</surname><given-names>Nicholas</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4169-4929</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-163911"><name><surname>Wu</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-164806"><name><surname>Zong</surname><given-names>Dali</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-164807"><name><surname>Sun</surname><given-names>Yilun</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-164808"><name><surname>Wong</surname><given-names>Nancy</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-164810"><name><surname>John</surname><given-names>Sam</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-164809"><name><surname>Wangsa</surname><given-names>Darawalee</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-164811"><name><surname>Ried</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-164812"><name><surname>Bunting</surname><given-names>Samuel F</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-164813"><name><surname>Pommier</surname><given-names>Yves</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-164797"><name><surname>Nussenzweig</surname><given-names>André</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8952-7268</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Laboratory of Genome Integrity</institution>, <institution>National Cancer Institute, NIH</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Developmental Therapeutics Branch</institution>, <institution>National Cancer Institute, NIH</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Genetics Branch</institution>, <institution>National Cancer Institute, NIH</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Department of Molecular Biology and Biochemistry</institution>, <institution>Rutgers University</institution>, <addr-line><named-content content-type="city">Piscataway</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-33764"><name><surname>Murphy</surname><given-names>Maureen</given-names></name><role>Reviewing editor</role><aff><institution>The Wistar Institute</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>andre_nussenzweig@nih.gov</email> (AN);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>14</day><month>02</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e53447</elocation-id><history><date date-type="received"><day>08</day><month>11</month><year>2019</year></date><date date-type="accepted"><day>12</day><month>02</month><year>2020</year></date></history><permissions><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-53447-v1.pdf"/><abstract><p>Topoisomerase II (TOP2) relieves topological stress in DNA by introducing double-strand breaks (DSBs) via a transient, covalently linked TOP2 DNA-protein intermediate, termed TOP2 cleavage complex (TOP2cc). TOP2ccs are normally rapidly reversible, but can be stabilized by TOP2 poisons, such as the chemotherapeutic agent etoposide (ETO). TOP2 poisons have shown significant variability in their therapeutic effectiveness across different cancers for reasons that remain to be determined. One potential explanation for the differential cellular response to these drugs is in the manner by which cells process TOP2ccs. Cells are thought to remove TOP2ccs primarily by proteolytic degradation followed by DNA DSB repair. Here, we show that proteasome-mediated repair of TOP2cc is highly error-prone. Pre-treating primary splenic mouse B-cells with proteasome inhibitors prevented the proteolytic processing of trapped TOP2ccs, suppressed the DNA damage response (DDR) and completely protected cells from ETO-induced genome instability, thereby preserving cellular viability. When degradation of TOP2cc was suppressed, the TOP2 enzyme uncoupled itself from the DNA following ETO washout, in an error-free manner. This suggests a potential mechanism of developing resistance to topoisomerase poisons by ensuring rapid TOP2cc reversal.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>Intramural Research Program</award-id><principal-award-recipient><name><surname>Nussenzweig</surname><given-names>André</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>Ellison Medical Foundation</institution></institution-wrap></funding-source><award-id>Senior Scholar in Aging Award AG-SS- 2633-11</award-id><principal-award-recipient><name><surname>Nussenzweig</surname><given-names>André</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Department of Defense Idea Expansion Award</institution></institution-wrap></funding-source><award-id>W81XWH-15-2-006</award-id><principal-award-recipient><name><surname>Nussenzweig</surname><given-names>André</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Department of Defense Idea Breakthrough Award</institution></institution-wrap></funding-source><award-id>W81XWH-16-1-599</award-id><principal-award-recipient><name><surname>Nussenzweig</surname><given-names>André</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>Alex Lemonade Stand Foundation Award</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Nussenzweig</surname><given-names>André</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>Intramural FLEX Award</award-id><principal-award-recipient><name><surname>Nussenzweig</surname><given-names>André</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All mouse breeding and experimentation followed protocols approved by the National Institutes of Health Institutional Animal Care and Use Committee (Protocol Numbers: EIB-064-3 and 17-042).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Sequencing data has been deposited in GEO under the accession code GSE140372</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Sciascia N</collab><collab>Wu W</collab><collab>Zong D</collab><collab>Sun Y</collab><collab>Wong N</collab><collab>Wangsa D</collab><collab>John S</collab><collab>Ried T</collab><collab>Bunting S</collab><collab>Pommier Y</collab><collab>Nussenzweig A</collab></person-group><year iso-8601-date="2019">2019</year><source>Suppressing Proteasome Mediated Processing of Topoisomerase II DNA-Protein Adducts Preserves Genome Integrity</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140372">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140372</ext-link><comment>NCBI Gene Expression Omnibus, GSE140372</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-53447-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>